Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.33 |
| ▸ | CA2 | P00918 | 5/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.30 |
| ▸ | CA7 | P43166 | 2/20 | 0.30 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12019206 | 0.84 | CA1 (0.31) | CA1CA2 | |
| SCHEMBL18133308 | 0.82 | CA1 (0.32) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL392504 | 0.77 | CA1 (0.36) | CA1CA2CA9 | |
| SCHEMBL2875483 | 0.76 | CA2 (0.48) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL2759902 | 0.74 | F2 (0.41) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL36242 | 0.74 | CA2 (0.52) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL12835130 | 0.73 | CA1 (0.38) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL24187580 | 0.72 | — | — | |
| SCHEMBL13266810 | 0.72 | — | — | |
| SCHEMBL21522351 | 0.71 | CA2 (0.50) | CA1CA2MMP1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2255201-B1 | FLUORESCENCE POLARIZATION HERG ASSAY | LIFE TECHNOLOGIES CORP (US) | 2014-08-06 | — | — | EP | disclosed |
| US-20120231541-A1 | FLUORESCENCE POLARIZATION hERG ASSAY | Life Technologies Corporation (US) | 2012-09-13 | — | — | US | disclosed |
| US-8133695-B2 | Fluorescence polarization hERG assay | Life Technologies Corporation (US) | 2012-03-13 | — | — | US | disclosed |
| EP-2255201-A2 | FLUORESCENCE POLARIZATION HERG ASSAY | Life Technologies Corporation (US) | 2010-12-01 | — | — | EP | disclosed |
| US-20090253148-A1 | FLUORESCENCE POLARIZATION hERG ASSAY | Life Technologies Corporation (US) | 2009-10-08 | — | — | US | disclosed |
| WO-2009108905-A2 | FLUORESCENCE POLARIZATION HERG ASSAY | Life Technologies Corporation (US) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253148-A1 | FLUORESCENCE POLARIZATION hERG ASSAY | TNNI3, TNNT2, KCNQ1 | CA1 4502/4885CA2 3669/4885MMP1 4862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.